Clinical Trial Update: Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating the combination of capivasertib and abiraterone for patients with metastatic hormone-sensitive prostate cancer and PTEN deficien…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Abiraterone acetate)
• Capivasertib (capivasertib)

Snippet

Sponsor: AstraZeneca | Conditions: Hormone-Sensitive Prostate Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING